benefitspro.com
An ALM exclusive brand
During this discussion, experts will share methods for identifying promising drug targets and biomarkers by leveraging linked clinico-genomic data in advancing therapeutic development and its application from research to clinical care.
In a rapidly evolving drug development landscape, it’s becoming increasingly important to leverage precision approaches to help characterize sub-populations of patients and uncover individual genetic drivers of safety and response – especially for germline disorders including cardiovascular. Genetic data combined with linked longitudinal clinical data, including full labs & patient vitals/demographics, has been shown to optimize target discovery and address the challenges of 'precision’ medicine development.
During this discussion, experts will share methods for identifying promising drug targets and biomarkers by leveraging linked clinico-genomic data in advancing therapeutic development and its application from research to clinical care.
Insights offered in this discussion:
Offered Free by: Helix
See All Resources from: Helix